The president of BD’s life sciences division, Dave Hickey, is officially planning his retirement, with the calendar marked for July 1. Hickey has overseen BD’s portfolio of scientific research tools ...

BD is finalizing a February 5 spinoff, creating a $17.5B life sciences company with a $40B addressable market.

Becton, Dickinson and Company BDX, popularly known as BD, is evaluating the divestment of its Life Sciences division as part of a broader strategic shift toward becoming a pure-play medtech company.

BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has completed the acquisition of Cellular Research, Inc. BD ...

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD leads in patient and healthcare worker safety ...

If BD’s ongoing hiring spree is any indication, the medtech giant—which recently reported nearly 20% growth in revenue for its fiscal year 2021—seems to be aiming to make an even bigger splash in 2022 ...